ImmuPharma Beheer

Beheer criteriumcontroles 3/4

De CEO ImmuPharma is Tim McCarthy, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 294.00K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.36% van de aandelen van het bedrijf, ter waarde € 27.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 10.3 jaar.

Belangrijke informatie

Tim McCarthy

Algemeen directeur

UK£294.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	10.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tim McCarthy's beloning veranderd ten opzichte van ImmuPharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-UK£2m
Mar 31 2024	n/a	n/a	-UK£3m
Dec 31 2023	UK£294k	UK£294k	-UK£3m
Sep 30 2023	n/a	n/a	-UK£3m
Jun 30 2023	n/a	n/a	-UK£3m
Mar 31 2023	n/a	n/a	-UK£3m
Dec 31 2022	UK£107k	UK£107k	-UK£4m
Sep 30 2022	n/a	n/a	-UK£5m
Jun 30 2022	n/a	n/a	-UK£6m
Mar 31 2022	n/a	n/a	-UK£7m
Dec 31 2021	UK£575k	UK£287k	-UK£8m
Sep 30 2021	n/a	n/a	-UK£8m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£7m
Dec 31 2020	UK£260k	n/a	-UK£7m
Sep 30 2020	n/a	n/a	-UK£6m
Jun 30 2020	n/a	n/a	-UK£5m
Mar 31 2020	n/a	n/a	-UK£6m
Dec 31 2019	UK£260k	n/a	-UK£6m
Sep 30 2019	n/a	n/a	-UK£7m
Jun 30 2019	n/a	n/a	-UK£7m
Mar 31 2019	n/a	n/a	-UK£7m
Dec 31 2018	UK£260k	n/a	-UK£7m
Sep 30 2018	n/a	n/a	-UK£7m
Jun 30 2018	n/a	n/a	-UK£7m
Mar 31 2018	n/a	n/a	-UK£7m
Dec 31 2017	UK£260k	n/a	-UK£6m

Compensatie versus markt: De totale vergoeding ($USD 369.20K ) Tim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tim McCarthy (68 yo)

3.3yrs

Tenure

UK£294,000

Compensatie

Mr. Timothy Paul McCarthy, XIV, also known as Tim, MBA, FCCA, is Independent Non-Executive Chairman at 4basebio PLC. He co-founded Alizyme PLC in 1995. Mr. McCarthy serves as the Chairman of ImmuPharma plc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy McCarthy	Chairman & CEO	3.3yrs	UK£294.00k	0.36% € 27.7k
Timothy Franklin	COO & Director	4.8yrs	UK£252.00k	0.13% € 9.8k
Lisa Baderoon	Head of Investor Relations & Non Executive Director	12.8yrs	UK£132.00k	0.38% € 29.4k
Jean-Marie Geiger	Head of Clinical Development	no data	geen gegevens	geen gegevens
Laura Mauran-Ambrosino	Chief Scientific Officer of ImmuPharma Biotech	2.2yrs	geen gegevens	geen gegevens
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.8yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 25I wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy McCarthy	Chairman & CEO	9.2yrs	UK£294.00k	0.36% € 27.7k
Timothy Franklin	COO & Director	3.3yrs	UK£252.00k	0.13% € 9.8k
Lisa Baderoon	Head of Investor Relations & Non Executive Director	3.3yrs	UK£132.00k	0.38% € 29.4k
Lee Simon	Member of Scientific Advisory Board	11.3yrs	geen gegevens	geen gegevens
Vibeke Strand	Member of Scientific Advisory Board	11.3yrs	geen gegevens	geen gegevens
David Isenberg	Member of Scientific Advisory Board	11.3yrs	geen gegevens	geen gegevens
Daniel Wallace	Member of Scientific Advisory Board	11.3yrs	geen gegevens	geen gegevens
Cees Kallenberg	Member of Scientific Advisory Board	11.3yrs	geen gegevens	geen gegevens
Laurence Reilly	Senior Independent Non-Executive Director	1.3yrs	UK£19.55k	geen gegevens
Sebastien R. Goudreau	Independent Non-Executive Director	1.3yrs	UK£1.17k	0.036% € 2.8k

10.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 25I zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.3 jaar).

ImmuPharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

ImmuPharma plc, Annual General Meeting, Jun 28, 2024

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director

No independent directors

ImmuPharma plc Announces Changes to Its Board of Directors

ImmuPharma plc, Annual General Meeting, Jun 30, 2023

ImmuPharma plc, Annual General Meeting, May 26, 2023

Recent updates

Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical Conference

ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024

ImmuPharma plc, Annual General Meeting, Jun 28, 2024

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director

New minor risk - Financial data availability

Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

No independent directors

ImmuPharma plc Announces Changes to Its Board of Directors

Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Market cap size

ImmuPharma plc, Annual General Meeting, Jun 30, 2023

ImmuPharma plc, Annual General Meeting, May 26, 2023

ImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating Polyneuropathy

Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d test

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market

Less than half of directors are independent

ImmuPharma plc to Report Q1, 2023 Results on Apr 25, 2023

ImmuPharma plc Appoints Ward Williams Limited as Company Secretary

First half 2022 earnings released: EPS: UK£0 (vs UK£0.015 loss in 1H 2021)

ImmuPharma PLC Provides Update on Lupuzor

ImmuPharma plc, Annual General Meeting, Jun 28, 2022

Full year 2021 earnings released: UK£0.032 loss per share (vs UK£0.034 loss in FY 2020)

ImmuPharma plc Provides Update on Lupuzor Progress to Phase 3 with Avion

No independent directors

ImmuPharma plc Provides Positive Data from Lupuzor/P140 Pharmacokinetic Study

ImmuPharma plc Provides an Update on the Lupuzor™ Pharmacokinetic Study, as Part of the New Optimized International Phase 3 Trial of Lupuzor™ in Lupus Patients

First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020)

Less than half of directors are independent

Independent Non-Executive Director Stéphane Robert Méry has left the company

Senior Independent Non-Executive Director Franco Di Muzio has left the company

Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the company

Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019)

ImmuPharma plc Appoints Ewa Flynn as Company Secretary

ImmuPharma plc Announces Guidance on Forthcoming International Phase 3 Trial of Lupuzor™ in Lupus Patients

ImmuPharma plc Announces Update on Submission to the FDA

ImmuPharma plc Announces Completion of Analysis from the IMMray and PanCan-d Verification Study

First half earnings released

Immunovia Announces Positive Results from the IMMray Pancan-D Verification Study

ImmuPharma plc announced that it expects to receive £2.35 million in funding from L1 Capital Pty. Limited, The Lind Partners, LLC

ImmuPharma plc to Report First Half, 2020 Results on Aug 20, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd